Triazolopyridine compounds as PIM kinase inhibitors

Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in t...

Full description

Saved in:
Bibliographic Details
Main Authors RAST BRYSON, CELESTE LAURA L, SCHLACHTER STEPHEN T, GROSS STEFAN D, TOPALOV GEORGE T, WRIGHT A. DALE, HICKS JULIE MARIE, ZHAO QIAN, DELISLE ROBERT KIRK, HICKEN ERIK JAMES, ROBINSON JOHN E, ALLEN SHELLEY, PHENEGER JED, MUNSON MARK C, LYSSIKATOS JOSEPH P, JACKSON LEILA J, KALLAN NICHOLAS C, DAVIS T. GREGG, MARMSATER FREDRIK P
Format Patent
LanguageEnglish
Published 24.03.2015
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
Bibliography:Application Number: US201314057882